Invention Grant
US07795389B2 Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
有权
拮抗TGF-β活性与各种胞外域TGF-β受体结合使用或作为融合蛋白
- Patent Title: Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
- Patent Title (中): 拮抗TGF-β活性与各种胞外域TGF-β受体结合使用或作为融合蛋白
-
Application No.: US11238172Application Date: 2005-09-28
-
Publication No.: US07795389B2Publication Date: 2010-09-14
- Inventor: LuZhe Sun , Andrew P. Hinck
- Applicant: LuZhe Sun , Andrew P. Hinck
- Applicant Address: US TX Austin
- Assignee: The Board of Regents of the University of Texas System
- Current Assignee: The Board of Regents of the University of Texas System
- Current Assignee Address: US TX Austin
- Agency: Fulbright & Jaworski LLP
- Main IPC: C07K14/00
- IPC: C07K14/00 ; A61K38/00 ; A61K38/16
Abstract:
Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGFβ) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.
Public/Granted literature
Information query
